In this video, Naim Alkhouri MD, FAASLD moderates a roundtable discussion with Amreen M. Dinani, MD, FRCPC and Mazen Noureddin, MD, MHSc on the practical clinical applications associated with starting and...
The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.
In this video, Naim Alkhouri, MD, discusses the relationship between waist circumference and non-alcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis, including the risk for NAFLD and fibrosis...
Individuals with NASH and significant liver fibrosis have a higher risk for serious liver-related outcomes compared with those with simple steatosis. Which endpoint should be a target for treatment: NASH...
In this video, Naim Alkhouri MD, FAASLD moderates a roundtable discussion with Amreen M. Dinani, MD, FRCPC and Mazen Noureddin, MD, MHSc on the practical clinical applications associated with starting and...
In this video, Naim Alkhouri, MD, discusses the relationship between waist circumference and non-alcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis, including the risk for NAFLD and fibrosis...
In this commentary, Robert G. Gish, MD, from the Hepatitis B Foundation, writes about the importance of early detection, prevention, and treatment of liver disease, as well as the role of physicians at...
In a recent study, researchers investigated the burden of disability based on the presence of various complications and the various potential etiologies in order to better understand trends in disability...
In this video, Cardiology Consultant Advisory Board Member Seth Baum, MD, talks about the many stakeholders that should be involved in the treatment of a patient with nonalcoholic steatohepatitis and...
